Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.

The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

Instil Bio Inc. (NASDAQ:TIL) saw its stock jump 10% after the company announced that the U.S. Food and Drug Administration ...

Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

近年来，抗体药物偶联物（ADC）已成为恶性肿瘤领域的研究热点，不断在肺癌的治疗中取得突破性进展。6 月 23 日，基于 TROPION-Lung05 研究和 TROPION-Lung01 研究积极结果，美国食品药品监督管理局（FDA）加速批准 ...

IOVA's ASCO update reiterates the value of Amtagvi in melanoma, but upcoming data in lung cancer and endometrial cancer in H2'25 might have a bigger ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

对EGFR基因突变的肺癌患者来说，“脑转移”已不再意味着“无药可救”。从第三代靶向药到新型ADC、从联合方案到ctDNA动态检测，临床正不断探索突破之道。希望随着未来更多临床研究的开展，脑转移治疗能更加精准、更加温柔，真正实现“带瘤长存”的目标。欢迎 ...

Experience the thrill of Winton Motor Raceway’s Fun Day, drive the iconic Supercars track, bring passengers, and enjoy a ...